Key takeaways
Cosentyx (secukinumab) and Humira (adalimumab) are both injectable medications used to treat various inflammatory and autoimmune conditions, but they work differently and have different uses. Cosentyx is an interleukin 17 (IL-17) inhibitor, while Humira is a biologic disease-modifying antirheumatic drug (DMARD) that blocks tumor necrosis factor (TNF). Cosentyx is typically injected once monthly, whereas Humira is usually injected every other week. Cosentyx is used for conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Humira treats a broader range of conditions, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Both medications can be used in children for certain conditions. Serious side effects for these medicatons include an increased risk of infections, but Humira also has warnings about potential risks for certain cancers and heart failure.
